<DOC>
	<DOCNO>NCT00194857</DOCNO>
	<brief_summary>This study design test two separate strategy treatment anemia ( low hemoglobin ) neutropenia ( low white blood cell ) HIV/HCV coinfected patient treat pegylated interferon ribavirin .</brief_summary>
	<brief_title>Treatment Anemia Neutropenia HIV/HCV Coinfected Patients Treated With Pegylated Interferon Ribavirin</brief_title>
	<detailed_description>This multi-center , randomize , open-labeled trial subject co-infected hepatitis C ( HCV ) human immunodeficiency virus type 1 ( HIV-1 ) na√Øve anti-HCV therapy . Subjects receive PEG interferon alfa-2b ( PEG-IFN ) 1.5 mcg/kg/week administer weekly plus ribavirin ( RBV ) 13 + 2 mg/kg/day . The goal study evaluate two different treatment option anemia neutropenia associate initiation pegylated interferon ribavirin . This result completion therapy , possibly well viral sustain response .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>hemoglobin &gt; 11 absolute neutrophil count &gt; 1,200 naive peg interferon ribavirin Prior treatment hepatitis C Pregnant nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>anemia</keyword>
	<keyword>dose reduction</keyword>
	<keyword>neutropenia</keyword>
	<keyword>hepatitis C virus</keyword>
	<keyword>human immunodeficiency virus</keyword>
</DOC>